---
layout: post
title: "Determination That BELVIQ (Lorcaserin Hydrochloride) Tablets, 10 Milligrams, and BELVIQ XR (Lorcaserin Hydrochloride) Extended-Release Tablets, 20 Milligrams, Were Withdrawn From Sale for Reasons of Safety or Effectiveness"
date: 2026-02-05 19:08:41 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2021-04449
original_published: 2021-03-04 00:00:00 +0000
significance: 8.00
---

# Determination That BELVIQ (Lorcaserin Hydrochloride) Tablets, 10 Milligrams, and BELVIQ XR (Lorcaserin Hydrochloride) Extended-Release Tablets, 20 Milligrams, Were Withdrawn From Sale for Reasons of Safety or Effectiveness

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** March 04, 2021 00:00 UTC
**Document Number:** 2021-04449

## Summary

The Food and Drug Administration (FDA or Agency) has determined that BELVIQ (lorcaserin hydrochloride) tablets, 10 milligrams (mg), and BELVIQ XR (lorcaserin hydrochloride) extended- release tablets, 20 mg, were withdrawn from sale for reasons of safety or effectiveness. The Agency will not accept or approve abbreviated new drug applications (ANDAs) for lorcaserin hydrochloride tablets, 10 mg and 20 mg.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2021/03/04/2021-04449/determination-that-belviq-lorcaserin-hydrochloride-tablets-10-milligrams-and-belviq-xr-lorcaserin)
- API: https://www.federalregister.gov/api/v1/documents/2021-04449

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
